Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).

Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D
Am J Kidney Dis. 2014 63 (2): 244-50

PMID: 24210590 · DOI:10.1053/j.ajkd.2013.09.016

MeSH Terms (15)

Aged Angiotensin II Type 1 Receptor Blockers Biomarkers Biphenyl Compounds Diabetes Mellitus, Type 2 Double-Blind Method Female Glomerular Filtration Rate Humans Irbesartan Kidney Failure, Chronic Losartan Male Middle Aged Tetrazoles

Connections (1)

This publication is referenced by other Labnodes entities:

Links